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Abstract
While pharmacogenetics - the correlation of genotype and response to medicines - currently has a
small but measurable impact on the prescribing practice of clinicians, the advent of the `personal
genome' is likely to change this significantly. Advances in high-throughput technologies aimed at
characterizing human genetic variation, including chip-based genotyping and next-generation
sequencing, are poised to provide a flood of information that will affect both pharmacogenetic
discovery and pharmacogenetic application in clinical practice. In order for this flood of information
to not overwhelm both researchers and clinicians alike, a variety of new and expanded information
management tools will be needed, including electronic medical records, bioinformatic algorithms
for analyzing sequence data, information management systems for storing, retrieving and interpreting
whole-genome sequence data, and pharmacogenetic decision tools for prescribers.
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The practice of modern medicine employs a broad array of drugs to cure acute conditions, such
as infections, and to manage chronic conditions, such as diabetes and heart disease. To be
approved for use for a given indication, a drug must be demonstrated to be both safe and
effective. However, this determination is based on aggregate measures, and individual response
to drugs can vary substantially. Some patients may show no response, some may have the
desired therapeutic response, while others may have adverse responses ranging from the merely
annoying to life threatening. This variation in response may be explained in part by diagnostic
uncertainty, environmental factors such as diet and interacting drugs, and by clinical factors
such as age and comorbid conditions. However, genetics has also been demonstrated to play
a major role in patient–patient variation in drug response. Individual genetic variation in
enzymes of drug metabolism and transport may lead to inadequate therapeutic responses owing
to the inability to absorb a drug, the inability to activate a prodrug, or excessive metabolism
and/or excretion of an active drug. Alternatively, the form of the drug target encoded in an
individual's genome may be insensitive to the drug [1]. Similarly, an individual may experience
adverse reactions to a drug if their genome encodes defective enzymes of drug metabolism,
resulting in an abnormally high exposure to the drug despite normal dosing. Pharmacogenetics
is the study of these effects of the `personal genome' on drug response.
© 2009 Future Medicine Ltd
Tel.: +1 919 966 9590 Fax: +1 919 966 5863 michael_wagner@unc.edu.
Financial & competing interests disclosure The author has no relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
NIH Public Access
Author Manuscript
Per Med. Author manuscript; available in PMC 2010 September 1.
Published in final edited form as:













The field of pharmacogenetics had its beginnings in the 1950s, with discoveries demonstrating
that individual variation in the levels of activity of enzymes involved in the metabolism of a
number of drugs correlated with adverse reactions to those drugs [2]. The advent of molecular
cloning and sequencing technologies enabled the identification of sequence variants in the
genes for these enzymes that are responsible for the variation in activity, and catalogs detailing
large numbers of these variants are now available online [101]. Chip-based genotyping
technologies have now made practical the testing of panels of genetic variants in large numbers
of individuals, effectively making available a limited but focused view of the `personal
genomes' of those individuals. Next-generation sequencing technologies are now coming into
widespread use and offer the prospect of complete, genome-wide information on an individual
basis, but raise new issues relating to the interpretation of that information in relation to
pharmacogenetics. This rapidly changing landscape has implications for both the discovery of
genetic variants with pharmacogenetic effects and the application into clinical practice.
Cataloging variation in the human genome: a prerequisite for
pharmacogenetic studies
Characterizing the extent of genetic variation in populations of interest and understanding its
distribution across the genome is a prerequisite for any genetic study, and this is certainly true
for pharmacogenetic studies. Discovery of most types of genetic variation depends on DNA
sequencing. Discovery can be focused on a single gene or a limited number of genes by using
molecular cloning or PCR to isolate those genes individually from the DNA of multiple
subjects. Comparison of the DNA sequences derived from different subjects allows for the
identification of sequence variants, which are positions in the genome where the DNA sequence
differs between individuals. Alternatively, an automated pipeline for random, `shotgun'
sequencing can identify variants distributed across the entire genome, as was done for the
HapMap project, which identified and validated more than 3.1 million SNPs [3,4]. The dbSNP
database [102] currently lists more than 6.5 million validated DNA sequence variants in
humans. The large majority of these are common variants, defined as having minor allele
frequencies (MAF) greater than 5%, but this is still only a fraction of the 15–20 million
sequence variants estimated to occur in human populations, approximately half of which are
expected to be uncommon variants (MAF < 5%) [3]. To identify 99% of both common and
uncommon variants (MAF > 0.1%) in the Caucasian population would require the sequencing
of approximately 1000 subjects [5], and a publicly funded project to obtain complete genome
sequences for this many subjects is now underway [103].
For the last 30 years, the sequencing methodology of choice has been the Sanger method [6].
Constant improvements in sequencing chemistry, gel-based sequencing equipment,
automation and software have resulted in the dramatic increases in sequencing throughput,
culminating in the determination of two versions of a consensus sequence for the human
genome [7,8]. These sequences now serve as the reference human genomes against which other
sequences can be compared for the identification of variants. However, the use of this
technology base for the determination of the complete sequences of multiple, individual human
genomes remains impractical owing to issues of cost and capacity. Novel technologies for
sequencing using highly multiplexed arrays of single DNA molecules or single molecule-
derived clusters of DNA (so-called next-generation sequencing) have emerged in the last few
years and represent a transformational advance for DNA sequencing, making the prospect of
individual, `personal genome sequences' conceivable [9]. Several complete human genome
sequences have been published using these technologies, and have identified a treasure trove
of novel genetic variation. For example, complete genome sequences of a Caucasian, three
Asians and an African individual yielded approximately 600,000, 420,000–590,000, and
1,000,000 novel variants, respectively [10–14]. The 1000 Genomes Project [103], currently
underway, is expected to catalog the vast majority of the remaining common genetic variation
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in the human genome. Given the means to comprehensively catalog human genetic variation,
the challenge for the field of pharmacogenetics is now twofold: first, to discover which of the
known or novel variants in the human genome are responsible for differences in individual
responses to drugs, and second, to apply these discoveries to clinical practice to allow for the
prescription of the safest and most effective drug for the individual patient.
Pharmacogenetic discovery
Patient cohorts
Demonstrating the pharmacogenetic effects of DNA variants requires the collection of a patient
cohort with documented medication and outcomes data as well as available DNA samples for
testing. Clinical trials and observational studies of patients in specialty clinics often provide
the best opportunity to collect the requisite data and samples. However, the number of subjects
with the phenotype of interest that can be collected in this way is often small, severely limiting
the power to detect pharmacogenetic effects. This is particularly true when the phenotype is
uncommon, as is often the case for adverse events. Postmarketing surveillance would seem to
be a logical source of patients experiencing adverse events. However, the current system in the
USA, the US FDA MedWatch system, with its reliance on voluntary submissions of adverse
event reports, is inadequate to provide the high quality patient data required in sufficient
numbers. Large epidemiological cohorts, such as the Framingham study in the USA [15] or
birth cohorts collected in a number of European countries, may provide a useful number of
subjects, particularly when these studies are linked to electronic medical and prescribing
records. Health maintenance organizations (HMOs) and pharmacy benefits managers (PBMs)
have large patient databases with electronic records, and a number of projects exploiting these
resources are already underway. For example, the Marshfield Clinic's personalized medicine
research project combines a biobank of DNA, plasma and serum samples from 20,000
consented individuals with access to the Clinic's medical records [16]. A number of pharmaco-
genetic studies based on this resource have been completed or are underway, including studies
of statins, metformin, warfarin and tamoxifen. Many of these studies were undertaken in
collaboration with academic researchers, demonstrating that academic/HMO partnerships are
feasible and can be very productive. Interest in pharmacogenetics by PBMs is exemplified by
Medco's (NJ, USA) project on the pharmacogenetic dosing of warfarin, where patients
initiating warfarin therapy are recruited in real-time from Medco's covered population [17].
The National Human Genome Research Institute (MD, USA) has organized the eMERGE
Network, a consortium of academic and private health-care systems, designed to `develop,
disseminate and apply approaches to research that combine DNA biorepositories with
electronic medical record (EMR) systems for large-scale, high-throughput genetic
research' [104]. The success of these efforts demon strates that the recruitment of subjects based
on electronic medical and prescribing records represents an important source of patient cohorts
for pharmacogenetic discovery in the future.
Testing for pharmacogenetic associations: the candidate gene approach
Once a cohort of patients has been identified, a choice must be made as to which variants to
genotype, how many variants to genotype and the appropriate genotyping technology platform
to be used. The traditional approach of testing variants one at a time with individual genotyping
assays may severely limit the number of variants that can be typed due to considerations of
cost, time and the amount of DNA available. It is then crucial to choose variants with high a
priori probability of involvement in the phenotype to be tested. For this reason,
pharmacogenetic discovery has, to date, largely relied on the so-called `candidate gene'
approach. Candidate genes for a particular drug are selected for evaluation based on pre-
existing knowledge relating to the drug target or to pathways of drug metabolism. A typical
candidate gene study usually involves one to a few genes. Variants in the candidate genes may
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be selected from databases or from published reports, based on their presumed or established
functional effects, or simply be distributed across the genes at some prespecified density.
Typically, one to a few variants are tested per gene. If sufficient variants are not available, the
candidate genes may be resequenced in a limited number of subjects (either randomly selected
controls or patients with the drug-response phenotype of interest) to identify genetic variants,
which may subsequently be genotyped in larger collections of patients with measured drug-
response phenotypes. A significant association of a drug-response phenotype with specific
alleles or genotypes for a given genetic variant is taken as evidence of an effect of the gene
containing that variant on drug response.
The candidate gene approach can be very successful when the correct candidates are chosen
and genetic variation within those candidates has been adequately surveyed. However, the
candidate gene approach will fail when the state of knowledge about metabolic pathways or
drug targets or target pathways for the drug under study is inadequate to allow the correct
choice of candidates for testing. For example, selective serotonin reuptake inhibitors are widely
used in the treatment of depression, and show widely varying efficacy and side-effect profiles
in individual patients. They have also been the subject of many pharmacogenetic studies
focusing on the drug target (serotonin reuptake transporter), downstream target pathways
(serotonin receptors) and genes involved in drug metabolism (CYP2D6 and CYP2C19).
However, results of most of these studies have been either negative or inconsistent [18],
suggesting that genes with significant pharmacogenetic effects must be sought outside of the
primary pharmacokinetic and pharmacodynamic pathways. The candidate gene approach may
also fail when the state of knowledge concerning genetic variation in the candidate genes is
inadequate. Variant discovery may have been carried out in an inadequate number of subjects
to successfully identify all relevant variants, particularly those occurring at a low frequency in
the discovery population, or may not have covered critical regions of the gene, such as
regulatory elements in introns or promoter regions. Patterns of genetic variation differ between
racial groups [19,20], and variants may have been described in subjects from a different racial
group than those being tested for pharmacogenetic effects.
Genome-wide association studies
Recent advancements in our understanding of the patterns of genetic variation across the human
genome, provided in large part by the HapMap project, as well as advances in highly
multiplexed genotyping technologies, have made possible an alternative to the candidate gene
approach: the genome-wide association study (GWAS). No knowledge of candidate genes is
required; the GWAS approach only assumes that genetic polymorphisms affecting the trait of
interest exist somewhere in the genome, and conducts an unbiased search across the entire
genome to find them. This is done by utilizing chip-based technologies to simultaneously (and
cost-effectively) genotype 500,000–1 million SNPs (the most common type of genetic variant
in the human genome) approximately evenly distributed across the genome. Even this
enormous number of variants is only a small fraction of the total number of variants known or
predicted to exist in the human population. However, genotypes for common SNPs in close
proximity to each other in the genome often tend to be highly correlated, due to the
coinheritance through human evolutionary history of the ancestral genotype combinations
present on small chromosomal segments, a phenomenon know as linkage disequilibrium.
Linkage disequilibrium between the SNPs tested on the chips and nearby, untested SNPs allows
a GWAS to capture the majority of genetic information at a much larger number of SNPs, with
the tested SNPs serving as proxies, or ̀ tags' for the information contained in the untested SNPs.
Patterns of linkage disequilibrium differ between racial groups and estimates of the proportion
of common variants for which the current generation of GWAS chips will yield more than 80%
of the total available information range from nearly 90% in Caucasians to less than 70% in
individuals of African descent [4].
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A GWAS will largely test for only the effects of common polymorphisms (MAF > 0.05).
Because the power to detect association decreases as the MAF decreases, the vast majority of
SNPs included on the commercially available genotyping chips are common SNPs.
Furthermore, of all the untested variants in the genome, only common polymorphisms will
show substantial linkage disequilibrium with the common SNPs tested on the chip. The large
number of association tests performed in a GWAS requires the use of stringent levels of
statistical significance (p-values of 10−7 or better) to avoid false-positive associations, and
consequently the power to detect associations at these genome-wide levels of significance for
variants with modest effects on phenotype may be quite low unless large numbers of subjects
are studied. Regions of segmental duplication in the human genome are typically under-
represented on GWAS genotyping chips, and many genes of potential pharmacogenetic
interest, such as cytochrome P450 gene families, tend to fall in these regions and may therefore
be inadequately covered in a GWAS. Despite these caveats, hundreds of GWAS studies have
been conducted in the last few years and have successfully identified scores of genes
contributing to the risk of many common human diseases and conditions, such as diabetes,
heart disease, asthma and obesity [105]. Many of the genes identified would not have been
considered candidates for the trait in question, demonstrating the value of the unbiased,
genome-wide approach for making novel discoveries.
The GWAS era in pharmacogenetics is just beginning, with only a small number of published
studies to date. Investigation of variation in therapeutic response to drugs include studies of
iloperidone treatment of schizophrenia [21], thiazide diuretic treatment of hypertension [22],
anti-TNF treatment in rheumatoid arthritis [23] and warfarin dosing [24,25]. The investigation
of adverse events includes studies of the elevation of serum alanine aminotransferase by
ximelagatran [26], QT interval prolongation by iloperi-done [27], bisphosphonate-related
osteonecrosis of the jaw [28], statin-induced myopathy [29] and drug-induced liver injury due
to flucloxacillin [30]. As in the common disease studies, many of the pharmacogenetics
associations detected are in genes that would not necessarily have been considered candidates
for the effect studied, providing novel insights into biology. The odds ratios for the variants
detected in pharmacogenetic GWAS have mostly been relatively high (>2), in contrast to the
variants found in common disease GWAS, where the odds ratios are usually quite low (<1.5).
However, this is not surprising in that most of the cohorts used in the pharmacogenetic studies
(several hundred to a thousand subjects) are quite small by GWAS standards, and therefore
were not sufficiently powered to detect variants with low odds ratios [31]. It is to be expected
that expanding the size of pharmacogenetics cohorts, perhaps by exploiting large-scale
epidemiological cohorts or HMO or pharmacy databases, will allow the detection of additional
variants contributing to drug response phenotypes at lower odds ratios.
An intermediate between the traditional candidate gene approach and GWAS is the use of chip-
based technology to genotype panels of variants from large numbers of potential candidate
genes. For example, the commercially available DMET™ plus chip (Affymetrix, CA, USA)
assays nearly 2000 variants in 225 genes thought to play a prominent role in adsorption,
distribution, metabolism and excretion (ADME) for a wide range of drugs [32]. By assaying
a number of variants several orders of magnitude smaller than a GWAS chip, the statistical
penalty for multiple testing is reduced, increasing the power to detect pharmacogenetic effects.
More alleles of each gene are assayed, over a broader range of MAF, providing a more
comprehensive view of the effects of these genes. DMET chips have been used in the discovery
of the pharmacogenetics effect of polymorphisms in the CYP4F2 gene on warfarin dose [33],
and polymorphisms in the CYP2C19 gene on clopidogrel efficacy [34]. It is likely that the use
of this and other custom chip designs will have a prominent place in pharmacogenetics studies
in the future.
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Common versus rare variants in pharmacogenetics
Given the fact that both the candidate gene approach and GWAS typically focus primarily on
common variants, it is fair to ask if rare variants should also be investigated for
pharmacogenetics effects. In studies of susceptibility to common, complex diseases, the effect
sizes of common polymorphisms are often small and account for a small percentage of total
variation in the phenotype[31,35]. Rare variants of high penetrance are also likely to contribute
to phenotypes of interest, and multiple rare variants in the many genes involved in pathways
affecting a given phenotype may, in aggregate, account for a larger fraction of the total variation
in the phenotype than common polymorphisms [36]. For example, Fearnhead and colleagues
identified 13 potentially deleterious, rare variants in five candidate genes involved in Wnt
signaling and mismatch repair from a series of patients with multiple colorectal adenomas and
a series of random controls [37]. A variant was present in 24.9% of patients compared with
only 12% of controls. The difference was highly significant [37]. Similarly, Sandilands and
colleagues showed that multiple null alleles of the filaggren gene, including uncommon
polymorphisms (MAF ~ 1%) and rare variants, were present in 47% of a series of Irish patients
with atopic dermatitis, compared with approximately 8% of controls [38]. In a series of papers,
Cohen and colleagues identified rare, nonsynonymous variants in six candidate genes related
to cholesterol metabolism by comprehensive sequencing of the exons of these genes in a series
of patient samples, and showed higher frequencies of these variants in individuals at the
extremes of the trait distributions [39–42], suggesting a causal role. Ji and colleagues screened
3000 patients from the Framingham Heart Study offspring cohort for rare variants in three
genes known to be involved in recessive diseases exhibiting extremely low blood pressure.
They found 30 rare variants of known or inferred functional effect in the heterozygous state in
49 subjects. These subjects had an average systolic blood pressure of 6.3 mmHg lower than
that of the entire cohort, and a reduced prevalence of hypertension [43].
In pharmacogenetics research, in contrast to disease susceptibility research, there are many
examples of common variants with high penetrance that account for a substantial portion of
the variation in response to certain drugs in human populations. However, there are also many
examples of uncommon to rare variants that have similar values of penetrance. For example,
the CYP2D6 gene, responsible for the metabolism of 25% of commonly used drugs, has been
extensively studied over the years, and over 75 variants have been described [101]. Most are
low frequency variants in any given population (though frequencies vary geographically), and
novel variants continue to be discovered as larger and more diverse groups of subjects are
examined. Not all of these CYP2D6 variants have been characterized functionally, but a
substantial fraction have been demonstrated to have little or no enzyme activity and would be
expected to have an impact on phenotypes related to CYP2D6 activity. Despite this evidence
of allelic diversity, most candidate gene studies will choose to genotype only the few variants
known to be common in the population being studied for reasons of cost and convenience, and
GWAS will miss the effects of all of the rare variants due to the fact that they will not be
adequately `tagged' by any of the common SNPs on the genotyping chip. Thus, in a discovery
setting, part of the effect of CYP2D6 on a pharmacogenetic phenotype in a population will be
missed, and in a clinical setting, individual patients carrying the rare, but untyped, variants will
be given incorrect information about their CYP2D6 status and their consequent risk for drug
reactions. The situation could be improved by using a multiplexed genotyping assay to allow
cost-effective coverage of a larger range of genetic variation. For example, the DMET Plus
chip assays 31 variants in the CYP2D6 gene, a substantial improvement over the handful of
common variants typically tested by individual assays. However, novel variants will still be
missed, and for some applications, multiplexed assays with the required content will not be
available.
Wagner Page 6













Resequencing to detect both common & rare variants in pharmacogenetic studies
The best way to insure the comprehensive identification and genotyping of all variants of a
gene, both common and rare, is to resequence that particular gene in each subject. For example,
complete sequencing of the BRCA1 and BRCA2 genes is routinely employed in a diagnostic
setting to identify variants conferring a risk for breast cancer in subjects with a family history
of the disease [44]. Traditional Sanger sequencing is adequate for resequencing of one or two
genes, but if large panels of genes must be resequenced for pharmacogenetic discovery or
pharmacogenetic risk prediction, this approach becomes impractical.
A variety of next-generation sequencing technologies are now commercially available [9]. All
rely on sequential fluorescent imaging of base incorporations in large scale arrays of single
DNA molecules or single molecule-derived clusters of DNA, though the enzymology and
chemistry of cluster generation and base incorporation differ between technologies. All these
technologies currently produce shorter individual sequences with higher per base error rates
than traditional Sanger sequencing, but rely on the enormous number of individual sequences
generated by the massively parallel nature of the approach to produce highly-redundant
coverage of each base, resulting in an accurate consensus sequence and accurate calling of
sequence variants. Next-generation sequencing technologies have recently been used to
determine the essentially complete genome sequences of five individuals [10–14], and both
tumor and constitutional genome sequences of a sixth individual [45]. However, despite the
enormous increases in throughput and reductions in cost per consensus base pair of these
approaches, applying whole-genome sequencing to the large number of individuals needed to
identify rare variants and demonstrate associations of those variants with phenotypes of interest
is still a large project, and is still prohibitively expensive. Inexpensive, complete, `personal
genomes' may be on the horizon, but that horizon is still a few years away.
An alternative to whole-genome sequencing is to apply next-generation technology to targeted
resequencing of specific genes. Two main approaches have been employed for targeting
specific regions of the genome for sequencing: hybridization-based sequence capture [46–49]
and multiplexed PCR amplification [50–53]. Each of these approaches has advantages and
disadvantages. Both are still in the early stages of development, and it is likely that
improvements in one or more of these methods in the near future will allow for the targeting
of larger regions with improved specificity and uniformity of coverage, and at reasonable cost.
Targeted resequencing using next-generation technology can easily produce megabases of
sequence covering extensive lists of candidate genes in a cost-effective and timely manner,
providing a comprehensive but focused view of the portion of an individual genome where
variants believed to have high a priori probabilities of affecting a phenotype of interest may
be found. Alternatively, a gene-targeted but genome-wide approach can be taken by targeting
the entire exome (the protein coding sequences for all genes, comprising approximately 1–2%
of the genome) [54].
In a recent paper, the exome was extracted from the complete genome sequence of Craig Venter
(one of a handful of complete individual genome sequences currently in the public domain)
and analyzed for potentially functional variants [55]. Venter's exome contained approximately
10,400 nonsynonymous single nucleotide variants ([SNVs] i.e., single nucleotide changes that
alter the amino acid encoded at a particular position in a protein), and about 15–20% of these
SNVs are rare in the human population. Bioinformatic analysis of the amino acid changes
produced by these variants indicated that about 1500 are likely to be functional. Only seven
nonsynonymous SNPs had annotations in the literature linking them to disease states, and all
of these had low odds ratios. No obvious correlations of any of these SNPs with the phenotype
of Dr Venter could be inferred. This study points out some of the difficulties of interpretation
that will be encountered in analyzing large-scale individual sequence data. In any whole-
genome sequence, whole-exome sequence, or even moderately large set of candidate gene
Wagner Page 7













sequences, a large number of variants will be found. Most of the common variants and
essentially all of the rare variants will have no annotation in the literature linking them with
disease states or response to medicines. Functional consequences can be assumed for SNVs
that result in protein truncation, or indels (insertion/deletion polymorphisms) that result in
frameshifts, or deletions that remove large portions of a gene. Bioinformatic analysis can infer
function for some of the nonsynonymous SNVs [56,57] and an even smaller portion of
regulatory variants. However, many variants will remain uncharacterized as to function, unless
high-throughput systems for functional screening can be devised. Even if a variant can be
demonstrated to have an effect on protein function, it remains to be shown whether this results
in an effect on phenotype. Moderately common to common variants discovered through
sequencing can be tested for association with a phenotype in a suitable patient cohort, as has
traditionally been done in both candidate gene studies and GWAS. For rare variants, this
approach will have insufficient power even in large cohorts, and new approaches must be
employed that will aggregate multiple rare variants of similar functional consequences for
analysis. For example, Cohen et al. [39] showed that multiple nonsynonymous variants in
candidate genes for high-density lipoprotein (HDL) cholesterol levels, taken together, were
enriched in patients at one extreme of the population distribution of HDL levels, suggesting
that variants that affect the function of these genes also affect HDL levels. Focusing
resequencing efforts on subjects collected from the extremes of the population distribution of
pharmacogenetic traits may prove to be a powerful approach to pharmacogenetic discovery.
Application of pharmacogenetics in clinical practice
Testing for individual genetic variants with known effects on drug response is already available
to clinicians and is being used to guide therapy to a limited extent. For example, testing for
common variants of CYP2C9 and VKORC1, which affect warfarin dose requirements, is
available from many clinical laboratories. Algorithms for calculating a starting dose of warfarin
based on genotype plus clinical factors have been developed [58] and are available online
[106], facilitating the interpretation and use of pharmacogenetic information by clinicians.
Testing for HLA-B*5701 in patients initiating abacavir therapy has become widespread, and
essentially eliminates cases of abacavir hypersensitivity [59]. Cetuximab, a monoclonal
antibody directed against the EGF receptor, is ineffective in treating colorectal cancers
containing somatic mutations in the KRAS oncogene, and KRAS genotyping is becoming
common in selecting an appropriate chemotherapy regimen for colorectal cancer patients
[60]. Many other single gene tests are available from both clinical laboratories and direct-to-
consumer genetics companies, with varying degrees of proof regarding clinical utility and cost-
effectiveness, and clinicians are generally left to their own devises in interpretation and
incorporation of the genetic results into their prescribing practices. Improvements in the
evidence base and development of widely accepted, detailed pharmacogenetic-based
prescribing guidelines for clinicians are needed to further the goal of personalizing prescribing
practices.
Future perspective
The field of pharmacogenetics is evolving rapidly today. While traditional candidate gene
studies are still being pursued, GWAS are becoming much more common, and deep
resequencing is seen as the next logical step. In the near term, as larger numbers of clinically
validated pharmacogenetic effects are identified, multiplexed, chip-based assays for panels of
variants are likely to become the preferred method for delivering personalized prescribing
based on individual genetic variation to large numbers of patients. The AmpliChip® (Roche,
Basal, Switzerland) was the first such device to gain US FDA approval for testing for
polymorphisms in the CYP2D6 and CYP2C19 genes. However, the AmpliChip has not come
into widespread use owing to its relatively high cost and limited coverage of drug metabolism
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genes. The DMET Plus chip, though not an FDA approved device, is a promising development
in this area, covering over 200 genes involved in drug metabolism and transport. Additional,
custom chips or alternative multiplexed genotyping technologies will undoubtedly be
developed for specific diagnostic needs and updated as novel pharmacogenetic variants are
discovered. These types of highly multiplexed assays for individual variants provide a view
into the `pharmacogenome' of an individual, and thus represent a focused version of the
`personal genome'.
The holy grail of the genome sequencing technology world is the US$1000 genome. As the
cost of genome sequencing declines towards this level over the next few years, clinicians face
the prospect of patients arriving in their offices with copies of their personal genome in hand.
What will be required to translate this overwhelming amount of information into clinical
decision making that takes into account the patient's inherited susceptibility to disease and their
likely reactions to the drugs that may be used to treat those diseases? First, an enormous
infrastructure to support the actual sequencing itself, the storage of the resulting sequences,
and the ability to access those sequences, will have to be developed. A single run of a next-
generation sequencing instrument produces approximately one terabyte of raw data, which
must be transferred from the sequencer to temporary storage space over high-speed networks,
analyzed on dedicated servers to extract sequence files, and assembled into completed genome
or target-gene sequences using special purpose software [61]. This infrastructure exists today
only within a few genome centers, but will have to be replicated and extended enormously to
allow worldwide dissemination of the technology. Given that the finished sequences
themselves can be generated, EMR systems adapted to handling sequence data will have to be
widely adopted across the healthcare system [62]. Second, improvements in bioinformatics
tools will be needed to assess the functional significance of rare variants identified in genes of
potential pharmacogenetic impact in individual patients' genome sequences. Third, major
advances will be needed in our understanding of how genetic variation affects responses to
commonly used drugs and other drugs with potentially severe side effects, and in the clinical
utility of using genetic information to guide prescribing of these drugs. Assuming that suitable
protections are put into place to protect patient privacy, the mining of large databases of
individual genome sequences coupled to drug response data in EMRs will lead to novel
pharmacogenetic discoveries and provide the evidence base for the clinical utility of
pharmacogenetic markers [63]. Fourth, as the pharmacogenetics knowledge base expands,
application of sequence data to clinical decision making will follow. Informatics-based
decision tools will be needed to help guide clinicians in interpretation of genome sequences
and personalization of prescribing practices based on those interpretations. Finally, outreach
and education programs will be needed to facilitate clinician understanding of the new tools
available to them to bring the benefits of personalized, genome-based medicine to their patients.
Executive summary
▪ Pharmacogenetics is the study of how individual genetic variation affects
responses to medicines.
▪ The field is rapidly evolving owing to the development of novel technologies for
detecting human genetic variation.
Variation in the human genome
▪ A total of 10–20 million sequence variants are believed to exist in the human
population.
▪ Roughly half are considered to be common variants (minor allele frequency > 0.05)
and half uncommon to rare variants.
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▪ Next-generation DNA sequencing technology now makes it feasible to catalog all
moderately common to common variants and to identify all variants in an
individual human genome.
Pharmacogenetic discovery
▪ The discovery of pharmacogenetic effects requires the assembly of a patient cohort
of suitable size with measurements of drug response.
▪ Most pharmacogenetic discovery to date has relied on testing the effects of variants
in candidate genes for drug metabolism or drug action.
▪ Genome-wide association studies represent a genome-wide, essentially unbiased
approach to discovering novel pharmacogenetic effects, and does not rely on the
adequacy of current knowledge relating to drug metabolism or mechanism of
action.
▪ While most pharmacogenetic studies to date have focused on the effects of
common variants, rare variants are also likely to play a role, and understanding the
role of rare variants will be important for making accurate predictions of risk for
individual patients.
▪ Resequencing using next-generation sequencing technology is the most practical
way to detect both common and rare variants in large numbers of patients.
▪ Resequencing can be applied to whole genomes, or can be focused on panels of
candidate genes.
▪ Interpretation of sequencing data can be challenging due to the large number of
variants discovered and uncertainty about the functional consequences of many
variants.
Clinical applications
▪ Testing for individual variants represents the state of pharmacogenetic application
in clinical practice today, and is having a small, but significant impact.
Future perspective
▪ The rapid development of genome technology is changing the pace of
pharmacogenetic research, and will change the way pharmacogenetics impacts the
practice of medicine in both quantitative and qualitative ways.
▪ New and expanded information management tools will be needed to capture the
benefits expected from the intersection of genome technology and
pharmacogenetics.
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